Abstract
Boron-containing compounds for neutron capture therapy (NCT) can be divided into three groups: compounds without specific accumulation in tumor, tumor-selective compounds, and compounds capable of incorporating into the structure of tumor cells. For the NCT of cancer patients, sodium mercaptododecaborate (BSH) and p-boronophenylalanine (BPA) were selected from several hundred of boron-containing compounds. In this paper, data on the distribution of BSH and BPAin the organism of animals with model tumors modeling those encountered in oncological patients are reviewed. Methods for increasing the boron uptake in tumor, based on the combined use of boron compounds and modification factors such as hyperthermia, effect of electric pulses on the tumor zone, administration of compounds possessing vasodilating properties and influencing the blood-brain barrier permeability, are considered.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
